Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jun 29;10(6):e003811. doi: 10.1136/jitc-2021-003811

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Clinical course of patient no 8. (A) Clinical course of patient no 8, who developed grade 3 lung injury after grade 2 cytokine release syndrome. (B) Chest X-ray (days 2, 9, and 14) and chest CT scan (days 5 and 9) of patient no 8. (C) Flow cytometry analysis of NY-ESO-1 tetramer–positive T cells in peripheral blood (PB) and bronchoalveolar lavage fluid (BALF) on day 10. Mononuclear cells were separated and were ex vivo stained with anti-CD8 antibody and NY-ESO-1 peptide/MHC tetramer. 25.0% of CD8⁺ T cells in PB were tetramer positive, and 53.6% of CD8⁺ T cells in BALF were also positive. TCR-T, T-cell receptor-engineered T cells.